Deletion of AT2 receptor prevents SHP-1-induced VEGF inhibition and improves blood flow reperfusion in diabetic ischemic hindlimb

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 12, 2017, Pages 2291-2300

  Paquin Veillette, Judith ^a   Lizotte, Farah ^a   Robillard, Stéphanie ^a   Béland, Raphaël ^a   Breton, Marc André ^a   Guay, Andréanne ^a   Despatis, Marc Antoine ^b   Geraldes, Pedro ^a,b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Angiotensin receptors; Diabetes mellitus; Reperfusion; SH2 domain containing phosphatase 1; Vascular endothelial growth factor; Vascular endothelial growth factor receptor

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PHOSPHOLIPASE C; PROTEIN KINASE B; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; PTPN6 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

AKT SIGNALING; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY LIGATION; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES CONTROL; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXPERIMENTAL DIABETES MELLITUS; FEMORAL ARTERY; GENE DELETION; GLUCOSE LEVEL; HINDLIMB MUSCLE; LIMB BLOOD FLOW; LIMB ISCHEMIA; MALE; MIGRATION INHIBITION; MOUSE; MRNA EXPRESSION LEVEL; MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN EXPRESSION LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION; ANIMAL; BLOOD FLOW; BOVINE; C57BL MOUSE; CELL CULTURE; CELL MOTION; CONVALESCENCE; DEFICIENCY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE MODEL; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; HINDLIMB; ISCHEMIA; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TIME FACTOR; VASCULARIZATION;

ANIMALS; BLOOD GLUCOSE; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE DELETION; GENOTYPE; HINDLIMB; ISCHEMIA; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOVERY OF FUNCTION; REGIONAL BLOOD FLOW; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85038265584     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.309977     Document Type: Article

References (45)

1. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433-1437.
2. Jeffcoate WJ. Wound healing-a practical algorithm. Diabetes Metab Res Rev. 2012;28(suppl 1):85-88. doi: 10.1002/dmrr.2235.
3. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-660. doi: 10.1038/nm0603-653.
4. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395. doi: 10.1038/74651.
5. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci. 2000;902:249-262; discussion 262.
6. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002;105:2012-2018.
7. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation. 2000;102:965-974.
8. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009;153:347-358. doi: 10.1016/j.jss.2008.04.023.
9. Tamarat R, Silvestre JS, Le Ricousse-Roussanne S, Barateau V, Lecomte-Raclet L, Clergue M, Duriez M, Tobelem G, Lévy BI. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol. 2004;164:457-466. doi: 10.1016/S0002-9440(10)63136-7.
10. Howangyin KY, Silvestre JS. Diabetes mellitus and ischemic diseases: molecular mechanisms of vascular repair dysfunction. Arterioscler Thromb Vasc Biol. 2014;34:1126-1135. doi: 10.1161/ATVBAHA.114.303090.
11. Tamarat R, Silvestre JS, Huijberts M, Benessiano J, Ebrahimian TG, Duriez M, Wautier MP, Wautier JL, Lévy BI. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci USA. 2003;100:8555-8560. doi: 10.1073/pnas.1236929100.
12. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, Peters K, Isner JM. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol. 1999;154:355-363. doi: 10.1016/S0002-9440(10)65282-0.
13. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S, Ferrara N, Symes JF, Isner JM. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol. 1995;147:1649-1660.
14. Li H, Fu X, Zhang L, Huang Q, Wu Z, Sun T. Research of PDGF-BB gel on the wound healing of diabetic rats and its pharmacodynamics. J Surg Res. 2008;145:41-48. doi: 10.1016/j.jss.2007.02.044.
15. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther. 2003;10:285-291. doi: 10.1038/sj.gt.3301969.
16. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM, Sluiter WJ, Tio RA, Quax PH, Gans RO, Dullaart RP, Hospers GA. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther. 2006;17:683-691. doi: 10.1089/hum.2006.17.683.
17. Lizotte F, Paré M, Denhez B, Leitges M, Guay A, Geraldes P. PKCδ impaired vessel formation and angiogenic factor expression in diabetic ischemic limbs. Diabetes. 2013;62:2948-2957. doi: 10.2337/db12-1432.
18. Regulska K, Stanisz B, Regulski M. The renin-angiotensin system as a target of novel anticancer therapy. Curr Pharm Des. 2013;19:7103-7125.
19. Favre GA, Esnault VL, Van Obberghen E. Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. Am J Physiol Endocrinol Metab. 2015;308:E435-E449. doi: 10.1152/ajpendo.00391.2014.
20. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of newonset diabetes. J Hypertens. 2005;23:463-473.
21. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28:2261-2266.
22. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol. 1990;137:7-12.
23. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996;27(3 pt 2):760-765.
24. Silvestre JS, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, Besnard S, Duriez M, Inagami T, Lévy BI. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res. 2002;90:1072-1079.
25. Alvarez SE, Seguin LR, Villarreal RS, Nahmias C, Ciuffo GM. Involvement of c-Src tyrosine kinase in SHP-1 phosphatase activation by Ang II AT2 receptors in rat fetal tissues. J Cell Biochem. 2008;105:703-711. doi: 10.1002/jcb.21866.
26. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest. 1991;88:921-933. doi: 10.1172/JCI115395.
27. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens Suppl. 1996;14:S95-S103.
28. Lakó-Futó Z, Szokodi I, Sármán B, Földes G, Tokola H, Ilves M, Leskinen H, Vuolteenaho O, Skoumal R, de Châtel R, Ruskoaho H, Tóth M. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. Circulation. 2003;108:2414-2422. doi: 10.1161/01.CIR.0000093193.63314.D9.
29. Munk VC, Sanchez de Miguel L, Petrimpol M, Butz N, Banfi A, Eriksson U, Hein L, Humar R, Battegay EJ. Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway. Hypertension. 2007;49:1178-1185. doi: 10.1161/HYPERTENSIONAHA.106.080242.
30. Benndorf R, Böger RH, Ergün S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res. 2003;93:438-447. doi: 10.1161/01.RES.0000088358.99466.04.
31. Falcón BL, Veerasingham SJ, Sumners C, Raizada MK. Angiotensin II type 2 receptor-mediated gene expression profiling in human coronary artery endothelial cells. Hypertension. 2005;45:692-697. doi: 10.1161/01. HYP.0000154254.89733.29.
32. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003;163:879-887. doi: 10.1016/S0002-9440(10)63448-7.
33. Mateos L, Perez-Alvarez MJ, Wandosell F. Angiotensin II type-2 receptor stimulation induces neuronal VEGF synthesis after cerebral ischemia. Biochim Biophys Acta. 2016;1862:1297-1308. doi: 10.1016/j. bbadis.2016.03.013.
34. Zhang H, Han GW, Batyuk A, et al. Structural basis for selectivity and diversity in angiotensin II receptors. Nature. 2017;544:327-332. doi: 10.1038/nature22035.
35. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J. 1997;325(pt 2):449-454.
36. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol. 1998;275(5 pt 1):C1216-C1223.
37. Cui T, Nakagami H, Iwai M, Takeda Y, Shiuchi T, Daviet L, Nahmias C, Horiuchi M. Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptormediated apoptosis in rat fetal vascular smooth muscle cell. Cardiovasc Res. 2001;49:863-871.
38. Matsubara H, Shibasaki Y, Okigaki M, et al. Effect of angiotensin II type 2 receptor on tyrosine kinase Pyk2 and c-Jun NH2-terminal kinase via SHP-1 tyrosine phosphatase activity: evidence from vascular-targeted transgenic mice of AT2 receptor. Biochem Biophys Res Commun. 2001;282:1085-1091. doi: 10.1006/bbrc.2001.4695.
39. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol. 2000;131:667-672. doi: 10.1038/sj.bjp.0703566.
40. Lee YH, Mungunsukh O, Tutino RL, Marquez AP, Day RM. Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells. J Cell Sci. 2010;123(pt 10):1634-1643. doi: 10.1242/jcs.063545.
41. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 1995;92:10663-10667.
42. Yamada H, Akishita M, Ito M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ, Horiuchi M. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension. 1999;33:1414-1419.
43. Fujita T, Mogi M, Min LJ, Iwanami J, Tsukuda K, Sakata A, Okayama H, Iwai M, Nahmias C, Higaki J, Horiuchi M. Attenuation of cuff-induced neointimal formation by overexpression of angiotensin II type 2 receptor-interacting protein 1. Hypertension. 2009;53:688-693. doi: 10.1161/HYPERTENSIONAHA.108.128140.
44. Brogelli L, Parenti A, Ledda F. Inhibition of vascular smooth muscle cell growth by angiotensin type 2 receptor stimulation for in vitro organ culture model. J Cardiovasc Pharmacol. 2002;39:739-745.
45. Qin Q, Wang J, Yan Y, Jing X, Du J, Deng S, Wu L, Liu Y, She Q. Angiotensin II induces the differentiation of mouse epicardial progenitor cells into vascular smooth muscle-like cells. Biochem Biophys Res Commun. 2016;480:696-701. doi: 10.1016/j.bbrc.2016.10.122.